Cardio Diagnostics Holdings Inc Dossier - Source-backed chat

Cardio Diagnostics Holdings Inc

CDIONASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.83

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.92Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $5.7M

Enterprise Value $6M

Shares Outstanding 2.9M diluted

Next Earnings Date16 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) is an early-stage precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence to develop advanced diagnostic tests. While its core products, Epi+Gen CHD™ and PrecisionCHD™, possess strong clinical validation and a favorable CMS gapfill payment rate of $854, the company is currently in a pre-revenue commercialization phase, generating only $2,680 in revenue for Q1 2026. Operations are heavily funded through dilutive at-the-market (ATM) equity financing, and the company faces long sales cycles and ongoing efforts to secure broad insurance coverage. Given the high execution risk, ineffective internal controls, and reliance on capital markets, a Hold recommendation is warranted until commercial traction and consistent revenue scaling are demonstrated.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Severe shareholder dilution from continuous reliance on at-the-market (ATM) equity sales to fund operations, combined with slow clinical adoption and long sales cycles that fail to offset high cash burn.

Base CaseCentral scenario

The company successfully establishes out-of-network commercial billing in Q2 2026 and slowly expands provider onboarding. Revenue begins to scale modestly in late 2026 and 2027, though the company remains dependent on ATM equity sales to fund its high cash burn. Medicare coverage remains a multi-year process.

Bull CaseUpside scenario

Rapid commercial adoption of Epi+Gen CHD™ and PrecisionCHD™ tests driven by the established $854 CMS reimbursement rate, successful international expansion into India, and scaling of community health partnerships.

Scenarios reflect our research view at the research date.

Key Investment Merits

Proprietary AI-driven Integrated Genetic-Epigenetic Engine with strong clinical validation and peer-reviewed data.
Established CMS gapfill payment rate of $854 per test for both Epi+Gen CHD™ and PrecisionCHD™.
Commissioned in-house high-complexity CLIA laboratory to support scalable testing operations.

Key Investment Risks

Extremely early commercial stage with negligible revenue ($2,680 in Q1 2026) and substantial net losses ($1.79M in Q1 2026).
High dilution risk due to heavy reliance on at-the-market (ATM) common stock sales to fund operations.
Ineffective internal disclosure controls and procedures as of the latest quarterly reporting period.

Thesis Invalidation Triggers

Inability to secure broad Medicare coverage or local coverage determinations (LCDs) over the next 12-24 months.
Failure to execute out-of-network commercial billing or secure meaningful commercial payor partnerships.
Inability to access capital markets or raise additional equity financing, threatening going concern status.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.